GYRE THERAPEUTICS INC (GYRE:NASDAQ)
$5.82 -0.04 (-0.6826%)
Analysed GYRE THERAPEUTICS INC (GYRE:NASDAQ) News Sources
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12-03-2026
yahoo.com
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
12-03-2026
yahoo.com
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
17-03-2026
yahoo.com
Exploring Three High Growth Tech Stocks In The US Market
27-03-2026
yahoo.com
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
04-05-2026
yahoo.com
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
07-05-2026
yahoo.com
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
07-05-2026
yahoo.com
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
12-05-2026
yahoo.com
New Strong Sell Stocks for May 27th
27-05-2026
yahoo.com
US High Growth Tech Stocks To Watch
28-05-2026
yahoo.com
What is the current price of GYRE THERAPEUTICS INC (GYRE:NASDAQ)?
The current price of GYRE THERAPEUTICS INC (GYRE:NASDAQ) is $5.82.
GYRE THERAPEUTICS INC (GYRE:NASDAQ) absolute price change since previous trading day?
The absolute price change of GYRE THERAPEUTICS INC (GYRE:NASDAQ) since the previous trading day is $-0.04.
GYRE THERAPEUTICS INC (GYRE:NASDAQ) percentage price change since previous trading day?
The percentage price change of GYRE THERAPEUTICS INC (GYRE:NASDAQ) since the previous trading day is -0.6826%.
What is the most recent average sentiment score for GYRE THERAPEUTICS INC (GYRE:NASDAQ)?
The most recent average sentiment score for GYRE THERAPEUTICS INC (GYRE:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for GYRE THERAPEUTICS INC (GYRE:NASDAQ)?
The most recent sentiment for GYRE THERAPEUTICS INC (GYRE:NASDAQ) is .
SEC-8K** Filing Available For GYRE THERAPEUTICS INC (GYRE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.